AU2001261607A1 - Method for treating a pancreatic disorder with a neurotoxin - Google Patents
Method for treating a pancreatic disorder with a neurotoxinInfo
- Publication number
- AU2001261607A1 AU2001261607A1 AU2001261607A AU6160701A AU2001261607A1 AU 2001261607 A1 AU2001261607 A1 AU 2001261607A1 AU 2001261607 A AU2001261607 A AU 2001261607A AU 6160701 A AU6160701 A AU 6160701A AU 2001261607 A1 AU2001261607 A1 AU 2001261607A1
- Authority
- AU
- Australia
- Prior art keywords
- neurotoxin
- treating
- pancreatic disorder
- pancreatic
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09629748 | 2000-07-31 | ||
US09/629,748 US6261572B1 (en) | 2000-01-11 | 2000-07-31 | Method for treating a pancreatic disorder with a neurotoxin |
PCT/US2001/015634 WO2002009742A1 (en) | 2000-07-31 | 2001-05-15 | Method for treating a pancreatic disorder with a neurotoxin |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001261607A1 true AU2001261607A1 (en) | 2002-02-13 |
Family
ID=24524317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001261607A Abandoned AU2001261607A1 (en) | 2000-07-31 | 2001-05-15 | Method for treating a pancreatic disorder with a neurotoxin |
Country Status (5)
Country | Link |
---|---|
US (1) | US6261572B1 (en) |
AR (1) | AR028939A1 (en) |
AU (1) | AU2001261607A1 (en) |
TW (1) | TWI321053B (en) |
WO (1) | WO2002009742A1 (en) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7838007B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating mammary gland disorders |
US7838008B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
US6337075B1 (en) * | 2000-01-11 | 2002-01-08 | Allergan Sales, Inc. | Methods for treating diabetes |
US6821520B2 (en) * | 2000-02-15 | 2004-11-23 | Allergan, Inc. | Clostridial toxin therapy for Hashimoto's thyroiditis |
US6464986B1 (en) * | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
US7273722B2 (en) * | 2000-11-29 | 2007-09-25 | Allergan, Inc. | Neurotoxins with enhanced target specificity |
CN1585642A (en) | 2001-11-15 | 2005-02-23 | 微观藻类公司 | Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission |
US7140371B2 (en) * | 2002-03-14 | 2006-11-28 | Allergan, Inc. | Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins |
US6688311B2 (en) * | 2002-03-14 | 2004-02-10 | Allergan, Inc. | Method for determining effect of a clostridial toxin upon a muscle |
US6894948B2 (en) | 2003-01-29 | 2005-05-17 | Pgs Exploration (Uk) Limited | Method for processing dual sensor seismic data to attenuate noise |
US7844338B2 (en) * | 2003-02-03 | 2010-11-30 | Enteromedics Inc. | High frequency obesity treatment |
US7444183B2 (en) * | 2003-02-03 | 2008-10-28 | Enteromedics, Inc. | Intraluminal electrode apparatus and method |
US20040172084A1 (en) * | 2003-02-03 | 2004-09-02 | Knudson Mark B. | Method and apparatus for treatment of gastro-esophageal reflux disease (GERD) |
US7613515B2 (en) * | 2003-02-03 | 2009-11-03 | Enteromedics Inc. | High frequency vagal blockage therapy |
US8071550B2 (en) * | 2003-03-03 | 2011-12-06 | Allergan, Inc. | Methods for treating uterine disorders |
US7947285B2 (en) * | 2003-12-12 | 2011-05-24 | Fein Seymour H | Methods for preventing post endoscopic retrograde cholangiopancreatography pancreatitis |
US7381698B2 (en) * | 2003-12-12 | 2008-06-03 | Chirhoclin, Inc. | Methods for treatment of acute pancreatitis |
WO2005110417A1 (en) * | 2004-05-07 | 2005-11-24 | Phytotox Limited | Phycotoxins and uses thereof |
WO2005110418A2 (en) * | 2004-05-07 | 2005-11-24 | Phytotox Limited | Transdermal administration of phycotoxins |
US7514088B2 (en) | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
US7811584B2 (en) * | 2004-06-30 | 2010-10-12 | Allergan, Inc. | Multivalent clostridial toxins |
AU2005279741B2 (en) | 2004-09-01 | 2011-10-06 | Allergan, Inc. | Degradable clostridial toxins |
US7429386B2 (en) * | 2004-09-03 | 2008-09-30 | Allergan, Inc. | Stretch mark treatment |
US7179474B2 (en) * | 2004-09-03 | 2007-02-20 | Allergan, Inc. | Methods for treating a buttock deformity |
AU2006227816B2 (en) | 2005-03-15 | 2012-04-05 | Allergan, Inc. | Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems |
US7731411B2 (en) * | 2005-04-04 | 2010-06-08 | Schlumberger Technology Corporation | Circulating fluid system for powder fluidization and method of performing same |
US7419675B2 (en) * | 2005-05-26 | 2008-09-02 | Allergan, Inc. | Method for treating peritoneal adhesions |
US8105611B2 (en) * | 2005-06-17 | 2012-01-31 | Allergan, Inc. | Treatment of autoimmune disorder with a neurotoxin |
US7672727B2 (en) * | 2005-08-17 | 2010-03-02 | Enteromedics Inc. | Neural electrode treatment |
US7822486B2 (en) * | 2005-08-17 | 2010-10-26 | Enteromedics Inc. | Custom sized neural electrodes |
US20070106338A1 (en) * | 2005-11-10 | 2007-05-10 | Electrocore, Inc. | Direct and Indirect Control of Muscle for the Treatment of Pathologies |
WO2009002437A2 (en) * | 2007-06-25 | 2008-12-31 | The Board Of Regents Of The University Of Texas System | Neurotoxin theraphy for postprandial hyperglycemia |
US8825164B2 (en) | 2010-06-11 | 2014-09-02 | Enteromedics Inc. | Neural modulation devices and methods |
US9005628B2 (en) | 2012-10-04 | 2015-04-14 | Dublin City University | Biotherapy for pain |
GB201312317D0 (en) | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
US10149893B2 (en) | 2013-09-24 | 2018-12-11 | Allergan, Inc. | Methods for modifying progression of osteoarthritis |
US10647750B2 (en) | 2015-01-09 | 2020-05-12 | Ipsen Bioinnovation Limited | Cationic neurotoxins |
GB201517450D0 (en) | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
GB201607901D0 (en) | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
EP3263710A1 (en) | 2016-07-01 | 2018-01-03 | Ipsen Biopharm Limited | Production of activated clostridial neurotoxins |
WO2018038301A1 (en) | 2016-08-26 | 2018-03-01 | Hugel Inc. | Stabilized liquid formulation of botulinum toxin and preparation method thereof |
US20210277071A1 (en) | 2016-09-29 | 2021-09-09 | Ipsen Biopharm Limited | Hybrid neurotoxins |
EP3470054B1 (en) | 2017-10-11 | 2023-09-20 | Hugel Inc. | Microstructure formulation techniques for botulinum toxin |
US10792400B2 (en) | 2017-10-12 | 2020-10-06 | Hugel Inc. | Microstructure formulation techniques for botulinum toxin |
US10525111B2 (en) | 2017-10-12 | 2020-01-07 | Hugel, Inc. | Microstructure formulation techniques for botulinum toxin |
JP7186228B2 (en) | 2018-02-26 | 2022-12-08 | イプセン バイオファーム リミテッド | Use of ultrasound to guide injection of non-cytotoxic proteases |
EP3825689A3 (en) | 2018-11-29 | 2021-09-15 | Hugel Inc. | A cell-based method for determining an activity of botulinum toxin |
US11925677B2 (en) | 2021-07-12 | 2024-03-12 | Penland Foundation | Treatment of diabetes and chronic pancreatitis using botulinum toxin |
US10960061B1 (en) | 2019-10-18 | 2021-03-30 | Penland Foundation | Treatment of amyotrophic lateral sclerosis using botulinum toxin |
US10967052B1 (en) | 2019-10-18 | 2021-04-06 | Penland Foundation | Treatment of dyslexia using botulinum toxin |
GB202103372D0 (en) | 2021-03-11 | 2021-04-28 | Ipsen Biopharm Ltd | Modified clostridial neurotoxins |
WO2023287729A1 (en) | 2021-07-12 | 2023-01-19 | Penland Foundation | Treatment of acute and chronic kidney disease |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5437291A (en) | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
EP0737074B1 (en) | 1993-12-28 | 2001-08-01 | Allergan Sales, Inc. | Botulinum toxins for treating hyperhydrosis |
US5766605A (en) | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
DK0773788T3 (en) | 1995-06-06 | 2003-09-01 | Allergan Inc | Improved Preparations and Methods for Chemodevelopment Using Neurotoxins |
JP3506172B2 (en) | 1997-03-13 | 2004-03-15 | 信越半導体株式会社 | Semiconductor wafer etching method |
US6143306A (en) * | 2000-01-11 | 2000-11-07 | Allergan Sales, Inc. | Methods for treating pancreatic disorders |
US6337075B1 (en) * | 2000-01-11 | 2002-01-08 | Allergan Sales, Inc. | Methods for treating diabetes |
-
2000
- 2000-07-31 US US09/629,748 patent/US6261572B1/en not_active Expired - Lifetime
-
2001
- 2001-05-15 AU AU2001261607A patent/AU2001261607A1/en not_active Abandoned
- 2001-05-15 WO PCT/US2001/015634 patent/WO2002009742A1/en active Application Filing
- 2001-05-22 TW TW090112259A patent/TWI321053B/en not_active IP Right Cessation
- 2001-06-01 AR ARP010102648A patent/AR028939A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
US6261572B1 (en) | 2001-07-17 |
AR028939A1 (en) | 2003-05-28 |
TWI321053B (en) | 2010-03-01 |
WO2002009742A1 (en) | 2002-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001261607A1 (en) | Method for treating a pancreatic disorder with a neurotoxin | |
AU6514201A (en) | Method for treating a movement disorder | |
AU2001238369A1 (en) | Method for treating thyroid disorders | |
AU2001231104A1 (en) | Methods for treating diabetes | |
AU2001265279A1 (en) | Transactional supply chain system and method | |
AU2001253502A1 (en) | A system and method for using loyalty points | |
AU2003272713A1 (en) | A method for treating severe tinnitus | |
AU2001263129A1 (en) | System and method for orthokeratology | |
AU2002348870A1 (en) | Method for defining a source and a drain and a gap inbetween | |
AUPR152100A0 (en) | Method for treating coral | |
AU2001277938A1 (en) | Method for treating angina | |
AU2001276005A1 (en) | Method for treating a neoplasm | |
AU2002241606A1 (en) | Method and system for collaborating advisors | |
AU2001261029A1 (en) | Method and apparatus for method and apparatus for self-adaptive code | |
AU2001238294A1 (en) | Light-emitting fiber, and method for making same | |
AU2001248372A1 (en) | Method for executing access control | |
AU2001232349A1 (en) | Modified cross-section fiber and production method therefor | |
EP1298216A4 (en) | Process for treating with enzyme | |
HK1044618A1 (en) | Production method for optical disc. | |
AU2001243297A1 (en) | Method for treating or preventing depression | |
AU6035300A (en) | A method and arrangement for controlling a tuneable laser | |
AU1332601A (en) | Strategic method for process control | |
AU2001279742A1 (en) | Method for online purchasing with high operating security | |
AU2000260661A1 (en) | Machinery alignment method and apparatus | |
AU2002243332A1 (en) | System and method for process mining |